Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (1428)	3/2/2000 7:20:00 AM
From: biowa	Respond to of 2001

Jeff, but have an exceptionally critical eye before buying, which is what I have been contemplating - without much conviction so far ?? On Janssen from the GLIA website: In collaboration with Janssen Pharmaceutica, N.V., a wholly owned subsidiary of Johnson and Johnson, Gliatech is identifying and characterizing compounds that will minimize the glial cell inflammatory response in Alzheimer's disease. The Company believes that these compounds may slow down or inhibit disease progression. Gliatech is pursuing a two-pronged approach to developing glial-related treatments for Alzheimer's disease. The first approach focuses on developing compounds that block the glial cell activation caused by beta amyloid, thus inhibiting cytokine release and the resulting inflammation. The second approach seeks to identify compounds that block the damaging complement proteins that are activated by the beta amyloid peptide. Gliatech has screened Janssen's library of compounds and has identified several compounds that offer therapeutic potential. These compounds are being used to develop more potent and selective compounds, which will be examined in animal models and additional preclinical tests. AND Finally, in October 1997, Janssen Pharmaceutica, a wholly owned subsidiary of Johnson & Johnson, extended its collaboration agreement with Gliatech for the Alzheimer's disease research program. biowa